Rebuilding After Sa...
Health Care: Drugs
Nektar Therapeutics Inc. (NKTR: NASDAQ)
$9.24 -0.49 | -5.04%
05/22/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:08/23/00
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| NKTR | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 8.31 | 51.79 | -19.92 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 13.60 | 0.13 | 0.04 |
| Net Income | 0.00 | 0.00 | |
| EPS | 0.35 | 0.00 |
Earnings for NKTR:
| EBITDA | -125.00 |
| REVENUE | 81.19M |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.44 | $0.23 | $-1.02 | $-0.71 |
| Number of Analysts | 6 | 5 | 7 | 6 |
| High Estimate | $-0.38 | $0.34 | $-0.91 | $-0.09 |
| Low Estimate | $-0.49 | $0.14 | $-1.21 | $-1.70 |
| Prior Year | $-0.30 | $-0.38 | $-1.49 | $-1.02 |
| Growth Rate (Year over Year) | -46.11% | 159.47% | 31.45% | 30.33% |
Portfolios with NKTR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
- Contributor10 Health Care Stocks With ...
- Contributor10 Mid-Caps With Upside
- Contributor10 Pharma Stocks With Upside
- ProDriehaus Capital
- UserSUPRATRADE 7 Top Stocks for...
- UserSUPRATRADE 10 Stock Picks F...
Latest NKTR Headlines from TheStreet
- 4 Stocks Under $10 Spiking Higher 02.22.13 | 03:02 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- J.P. Morgan Healthcare Confab Live Blog Day Three 01.09.13 | 10:01 am
- Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab 01.04.13 | 08:01 am
- A Buysider's Preview of Biotech's Biggest Conference 01.02.13 | 07:01 am
- AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study 11.13.12 | 10:11 am
- FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs 11.12.12 | 10:11 am
- 21 Most Volatile Biopharma Stocks Closing Out 2012 11.05.12 | 06:11 am
- 5 Stocks Poised for Breakouts 09.28.12 | 01:09 pm
- Nektar Therapeutics Is a Short 09.12.12 | 07:09 am
Press Releases for NKTR
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 2013 UBS Global Healthcare Conference In New York City - PR Newswire 05.16.13 | 06:05 pm
- Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia - PR Newswire 04.16.13 | 05:04 am
- Nektar Therapeutics To Present At The 33rd Annual Cowen And Company Healthcare Conference In Boston - PR Newswire 03.01.13 | 04:03 pm
- AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation - PR Newswire 02.26.13 | 06:02 am
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 31st Annual J.P. Morgan Healthcare Conference In San Francisco, CA - PR Newswire 01.04.13 | 08:01 am
- Nektar To Announce Financial Results For The Third Quarter Of 2012 On Tuesday, November 13, 2012, After Close Of U.S.-Based Financial Markets - PR Newswire 11.06.12 | 05:11 pm
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The UBS 2012 Global Life Sciences Conference In New York City - PR Newswire 09.13.12 | 09:09 am
- Nektar To Announce Financial Results For The Second Quarter Of 2012 On Thursday, August 9, 2012, After Close Of U.S.-Based Financial Markets - PR Newswire 08.02.12 | 03:08 pm
- Nektar Therapeutics Announces Private Placement Of $125 Million Of Senior Secured Notes Due In 2017 - PR Newswire 07.10.12 | 08:07 am
- Nektar To Host Investor And Analyst R&D Day In New York City - PR Newswire 04.10.12 | 08:04 am
Partner Headlines for NKTR
- UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform - Benzinga 11.13.12 | 09:11 am
- UPDATE: Jefferies & Company Downgrades Nektar Therapeutics to Hold, Lowers PT - Benzinga 11.12.12 | 09:11 am
- Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192 - Benzinga 09.18.12 | 09:09 am
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- The Age Of Personalized Medicine Has Arrived - Seeking Alpha 03.08.12 | 09:03 am
- Company News for March 1, 2012 - Corporate Summary - Zacks 03.01.12 | 10:03 am
- What's It Going To Take To Get Salix Cheap? - Seeking Alpha 02.29.12 | 08:02 am
- Nektar Therapeutics Presents Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer - Benzinga 09.10.11 | 04:09 pm
- 10 Stocks With Bullish Momentum Backed By Strong Top Line Growth - Seeking Alpha 08.24.11 | 08:08 am
- 14 Oversold Stocks Trading Near Lows but Being Bought Up by the Smart Money - Seeking Alpha 07.12.11 | 09:07 am
